1. Home
  2. VGAS vs SCYX Comparison

VGAS vs SCYX Comparison

Compare VGAS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verde Clean Fuels Inc.

VGAS

Verde Clean Fuels Inc.

HOLD

Current Price

$1.75

Market Cap

37.3M

Sector

Industrials

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.95

Market Cap

41.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGAS
SCYX
Founded
2007
1999
Country
United States
United States
Employees
12
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.3M
41.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
VGAS
SCYX
Price
$1.75
$0.95
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
17.9K
407.2K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$0.57
52 Week High
$3.92
$1.29

Technical Indicators

Market Signals
Indicator
VGAS
SCYX
Relative Strength Index (RSI) 50.27 47.35
Support Level $1.52 $0.73
Resistance Level $2.06 $0.96
Average True Range (ATR) 0.17 0.07
MACD -0.01 -0.02
Stochastic Oscillator 33.33 9.52

Price Performance

Historical Comparison
VGAS
SCYX

About VGAS Verde Clean Fuels Inc.

Verde Clean Fuels Inc is a renewable energy company specializing in the conversion of synthesis gas, or syngas, derived from diverse feedstocks, such as biomass, MSW, and mixed plastics, as well as natural gas (including synthetic natural gas) and other feedstocks, into liquid hydrocarbons that can be used as gasoline through a proprietary liquid fuels technology, the STG process.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: